CurrentCignaPolicy IP0040

Short-acting beta2-agonist inhalers (albuterol/levalbuterol) formulary exception criteria

Cigna coverage policy IP0040 defines medical necessity criteria for coverage of specific short-acting beta2-agonist inhaler products (various branded albuterol and levalbuterol HFA and dry-powder devices) when formulary exceptions are requested. It lists initial and reauthorization requirements, authorization durations, and related clinical background and guideline context.

Policy Summary

PayerCigna

PolicyShort-acting beta2-agonist inhalers (albuterol/levalbuterol) formulary exception criteria

Policy CodePolicy IP0040

Change TypeNo material change

Effective Date

Next Review Date

Key ActionFor coverage of any listed branded short-acting beta2-agonist, submit documentation showing failure, contraindication, or intolerance to albuterol sulfate inhalation aerosol generics for ProAir and Proventil (and for some products, documentation that a spacer was tried if inability to coordinate MDI actuation is the issue).

SourceLink

POLICY UPDATE CHANGES

No material clinical or coverage changes

8Products listed with criteria

12Initial authorization (months)

12Reauthorization (months)

Coverage Summary

Trek Health ingests and normalizes Transparency in Coverage data and payer policy updates to give provider organizations a clear view of how commercial reimbursement behaves across markets, payers, and services. Our platform transforms raw payer disclosures into structured intelligence that supports contract evaluation, payer negotiations, and service line strategy. By combining market benchmarks with ongoing policy visibility, Trek helps teams identify variability, risk, and opportunity in commercial reimbursement. The result is faster insight, stronger negotiating positions, and more informed financial decisions.

Cigna Coverage Policy IP0040 defines medical-necessity formulary-exception criteria for specific short-acting beta2-agonist inhalers (albuterol and levalbuterol) intended for patients age ≥ 4 years. The policy's coverage stance is covered_with_criteria, with both initial authorization and reauthorization durations of 12 months (initial approval duration up to 12 months; reauthorization approval duration up to 12 months).

Medical Necessity Criteria

Reauthorization Criteria

Conditions for continued coverage

ALL of the following

Initial criteria are met
There is documentation of beneficial response to therapy.

Authorization Duration

ANY of the following

Initial approval duration is up to 12 months.
Reauthorization approval duration is up to 12 months.

Referenced Products / Codes

Referenced products (no specific billing codes provided in document)mixed

albuterol sulfate HFA (Prasco)	listed as non-covered product supported by formulary exception criteria
levalbuterol tartrate inhalation aerosol	listed as non-covered product supported by formulary exception criteria
ProAir Digihaler (albuterol sulfate inhalation powder)	listed
ProAir HFA (albuterol sulfate inhalation aerosol)	listed
ProAir RespiClick (albuterol sulfate inhalation powder)	listed
Proventil HFA (albuterol sulfate inhalation aerosol)	listed
Ventolin HFA (albuterol sulfate inhalation aerosol)	listed
Xopenex HFA (levalbuterol tartrate inhalation aerosol)	listed

No specific billing, NDC, CPT, or HCPCS codes are provided in the policy; the document lists referenced product names only in its product/code table. Receipt of sample product is explicitly stated as not satisfying criteria requirements.

Provider Actions & Documentation Requirements

Prior Authorization

Formulary exception requires documentation of failure/contraindication/intolerance

For coverage of any listed branded short-acting beta2-agonist, submit documentation showing failure, contraindication, or intolerance to albuterol sulfate inhalation aerosol generics for ProAir and Proventil (and for some products, documentation that a spacer was tried if inability to coordinate MDI actuation is the issue).

Documentation Required

Beneficial response documentation for reauthorization

To reauthorize therapy, provide documentation that initial medical necessity criteria were met and that the patient has a beneficial response to the short-acting beta2-agonist therapy.

Billing Rule

Sample product not acceptable as evidence

Receipt of sample product does not satisfy any criteria requirements for coverage.

Background & Clinical Context

The policy supports medical necessity review for formulary exceptions for several short-acting beta2-agonist inhalers (albuterol and levalbuterol) indicated for relief of acute asthma symptoms and prevention of exercise-induced bronchospasm in patients ≥ 4 years. ProAir Digihaler contains a built-in electronic module that records inhaler events and can transmit data to a mobile application, but use of the application is not required and there are no data showing the application improves safety, effectiveness, or clinical outcomes.

Guideline alignment: the GINA and GOLD global strategies do not prefer any single product within this class; they refer to these agents as a class of medications.

Formulary exception: Request for coverage of a non-formulary product when medical necessity criteria (failure, contraindication, or intolerance to formulary alternatives) are documented.